Self-report. In the study of Da Vinci [1] The quality of lipid-lowering treatment was determined as primary and secondary prevention of cardiovascular disease in relation to the European guidelines for 2016 and 2019. The study included 3,000 patients in primary prevention and 2,888 patients in secondary prevention, studied in 18 European countries, and who received lipid-lowering therapy in The last 12 months. Between June 2017 and November 2018, patients’ most recent LDL cholesterol levels were observed in connection with hospital or outpatient visits and their comparison with risk-based treatment goals according to the above guidelines. Among high-risk individuals, high-dose monotherapy with statins was administered to 20 percent of patients in primary prevention and 38 percent in secondary prevention. The risk-based treatment goal for LDL value according to the 2016 guidelines was only achieved at 54 percent (95 percent confidence interval [95KI] 52-56) of patients, while only 33 percent (95KI 32-35) achieved the most stringent treatment goal of 2019. The treatment outcomes for 315 patients recruited from 6 Swedish primary care centers and hospitals did not differ significantly from those in the rest Europe.

The study showed a clear deficiency in both European and Swedish clinical practice in terms of accessing the 2016 and 2019 guidelines. Increased use of other lipid-lowering therapies in addition to statins, such as ezetimibe and PCSK9 (PPCs / Quixin type 9 inhibitors), could To reduce the gap between lipid levels achieved and recommended treatment goals.